Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Nicolas Rouyrre"'
Autor:
Bruce AC Cree, Douglas L Arnold, Robert J Fox, Ralf Gold, Patrick Vermersch, Ralph HB Benedict, Amit Bar-Or, Daniela Piani-Meier, Nicolas Rouyrre, Shannon Ritter, Ajay Kilaru, Goeril Karlsson, Gavin Giovannoni, Ludwig Kappos
Publikováno v:
Multiple sclerosis (Houndmills, Basingstoke, England), vol 28, iss 10
Background: Siponimod significantly reduced the risk of confirmed disability progression (CDP), worsening in cognitive processing speed (CPS), relapses, and magnetic resonance imaging (MRI) measures of brain atrophy and inflammation versus placebo in
Autor:
Ralf Gold, Ludwig Kappos, Amit Bar-Or, Patrick Vermersch, Gavin Giovannoni, Robert J Fox, Nicolas Rouyrre, Goril Karlsson, Bruce AC Cree
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 93:A27.1-A27
BackgroundSiponimod, a selective sphingosine 1-phosphate receptor modulator, demonstrated clini- cally relevant effects in a typical secondary progressive multiple sclerosis (SPMS) population in the Phase 3 EXPAND study, with 21% and 26% reductions i
Autor:
Christian Wolf, Ludwig Kappos, Daniela Piani Meier, Nicolas Rouyrre, Amit Bar-Or, Davorka Tomic, Patrick Vermersch, Bruce A.C. Cree, Gavin Giovannoni, Robert J. Fox, Baldur Magnusson, Göril Karlsson, Ralf Gold, Frank Dahlke
Publikováno v:
Multiple Sclerosis (Houndmills, Basingstoke, England)
Multiple sclerosis (Houndmills, Basingstoke, England), vol 27, iss 10
Multiple sclerosis (Houndmills, Basingstoke, England), vol 27, iss 10
Background: In multiple sclerosis, impact of treatment on disability progression can be confounded if treatment also reduces relapses. Objective: To distinguish siponimod’s direct effects on disability progression from those on relapses in the EXPA
Autor:
Nicolas Rouyrre, Nicholas Adlard, Richard Nicholas, Evelyn Worthington, Chris Cameron, Anja Haltner, Imtiaz A. Samjoo, Frank Dahlke
Background: Siponimod, interferon beta-1a (IFNβ-1a), IFNβ-1b and natalizumab have been evaluated as treatments for secondary progressive multiple sclerosis (SPMS) in separate randomized controlled trials (RCTs), but not head-to-head. These trials i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86a05ba31adc93eee7583fae4ce89f44
Autor:
Marc Peeters, Eric Baudin, David J. Gross, Maurizio Voi, James C. Yao, Kjell Öberg, Nicolas Rouyrre, Marianne Pavel, John D. Hainsworth
Publikováno v:
Ann Oncol
Annals of oncology
Annals of oncology
Background: In the phase 3 RADIANT-2 study, everolimus plus octreotide long-acting repeatable (LAR) showed improvement of 5.1 months in median progression-free survival versus placebo plus octreotide LAR among patients with advanced neuroendocrine tu
Publikováno v:
Statistics in medicineREFERENCES. 38(23)
The treatment effect in subgroups of patients is often of interest in randomized controlled clinical trials, as this may provide useful information on how to treat which patients best. When a specific subgroup is characterized by the absence of certa
Publikováno v:
Lancet (London, England). 388(10041)
Autor:
David Neal Franz, Özlem Anak, Francois Ringeisen, Jorge Gallo, Gabriel N. Hortobagyi, Alain Ravaud, Marianne Pavel, Robert J. Motzer, Hope S. Rugo, Nicolas Rouyrre, James C. Yao
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology, vol 27, iss 3
Annals of Oncology
Annals of Oncology
In a meta-analysis of clinical studies, stomatitis did not adversely affect PFS in everolimus-treated patients, and in some studies, trended toward longer PFS than in patients without stomatitis. These results support continued use of everolimus, wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3def8902d3119085c6fa0528a18988e
https://escholarship.org/uc/item/67t7z6cg
https://escholarship.org/uc/item/67t7z6cg
Publikováno v:
Statistics in Medicine. 30:1618-1627
Traditional phase III non-inferiority trials require compelling evidence that the treatment vs control effect bfθ is better than a pre-specified non-inferiority margin θ(NI) . The standard approach compares this margin to the 95 per cent confidence
Autor:
J. Tabernero, Ranson, V Duval, J. Baselga, Wolfgang Hackl, Jordi Rodon, J. R. Infante, Antonio P. Silva, H. A. Burris, Nicolas Rouyrre
Publikováno v:
Cancer Research. 70:P6-15
Background: The PI3K pathway plays a major role in cancer cell growth and survival and is the most frequently altered pathway in cancer. BEZ235 is a potent and highly specific oral PI3K/mTOR inhibitor. Administered as hard-gelatine capsule, BEZ235 wa